

Akers Biosciences Inc  
Form NT 10-Q  
August 14, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

OMB APPROVAL

OMB Number: 3235-0058

Expires: August 31, 2015

Estimated average burden hours per response ... 2.50

SEC FILE NUMBER

**000-55013**

CUSIP NUMBER

**NOTIFICATION OF LATE FILING**

(Check one): ☐ Form 10-K ☐ Form 20-F ☐  
Form 11-K ☒ Form 10-Q ☐  
Form 10-D ☐ Form N-SAR ☐  
Form N-CSR

For Period Ended: June 30, 2015

☐ Transition Report on Form  
10-K

☐ Transition Report on Form  
20-F

☐ Transition Report on Form  
11-K

☐ Transition Report on Form  
10-Q

☐ Transition Report on Form  
N-SAR

For the Transition Period Ended:

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

**Akers Biosciences, Inc.**

Full Name of Registrant

Former Name if Applicable

**201 Grove Road**

Address of Principal Executive Office (*Street and Number*)

**Thorofare, NJ 08086**

City, State and Zip Code

## PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

☐ (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

## PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Registrant was informed of a subsequent event that required updating of financial statements just prior to the filing date and management could not complete the required financial statements and Management's Discussion and Analysis of such financial statements without undue hardship and expense to the Registrant by August 14, 2015.

## PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

**Raymond F. Akers, Jr., Ph.D** (856) **848-2116**  
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that

Edgar Filing: Akers Biosciences Inc - Form NT 10-Q

the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes ☒ No ☐

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**AKERS BIOSCIENCES INC.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2015 By: */s/ Raymond F. Akers, Jr., Ph.D*  
Name: Raymond F. Akers, Jr., Ph.D  
Title: Executive Chairman

